# Technology Appraisal Virtual Committee Meeting

# [Committee D]

**Minutes:** **Confirmed**

**Date: Tuesday 6 October 2020**

## Committee Members Present:

* Chair Professor Gary McVeigh Present for all notes
* Vice Chair Dr Lindsay Smith Present for all notes
* Nabeel Alsindi Present for notes 1 to 15
* Carlo Berti Present for notes 9 to 23
* Matt Bradley Present for all notes
* Sofia Dias Present for all notes
* Rachel Elliott Present for all notes
* Professor Paula Ghaneh Present for all notes
* Rebecca Harmston Present for all notes
* Robert Hodgson Present for all notes
* Dr Bernard Khoo Present for all notes
* Dr Soo Fon Lim Present for all notes
* Dr Guy Makin Present for all notes
* Professor David Meads Present for all notes
* Giles Monnickendam Present for all notes
* Dr Malcolm Oswald Present for all notes
* Baljit Singh Present for all notes
* John Watkins Present for all notes
* Ed Wilson Present for all notes
* Ugochi Nwulu Present for all notes

### NICE Staff In attendance:

* Jasdeep Hayre, Associate Director, NICE, Present for notes 9 to 15
* Linda Landells, Associate Director, NICE, Present for notes 1 to 8 & 16 to 23
* Gavin Kenny, Project Manager, NICE, Present for notes 9 to 15
* Kate Moore, Project Manager, NICE, Present for all notes
* Christian Griffiths, Technical Adviser, NICE, Present for notes 1 to 8
* Adam Brooke, Technical Analyst, NICE, Present for notes 1 to 8
* Caron Jones, Technical Adviser, NICE, Present for notes 9 to 15
* Victoria Kelly, Technical Adviser, NICE, Present for notes 16 to 23
* Mandy Brereton, Committee Operations Assistant Project Manager, NICE, Present for notes 1 to 8
* Sandra Robinson, Corporate Office Coordinator, NICE, Present for notes 1 to 5, 9 to 12 & 16 to 20
* Heidi Livingstone, Corporate Office Coordinator, NICE, Present for notes 1 to 5, 9 to 12 & 16 to 20
* Laura Marsden, Committee Operations Coordinator, NICE, Present for all notes
* Ismahan Abdullah, Technology Appraisals Administrator, NICE, Present for notes 9 to 15
* Celia Mayers, Technology Appraisals Administrator, NICE, Present for notes 1 to 8 & 16 to 23

## ERG Representatives in attendance:

* Hannah Penton, Kleijnen Reviews Ltd, Present for notes 1 to 5
* Rob Riemsma , Kleijnen Reviews Ltd, Present for notes 1 to 5
* Maiwenn Al, Kleijnen Reviews Ltd, Present for notes 1 to 5
* Keith Cooper, Southampton Health Technology Assessment Centre, Present for notes 9 to 12
* Geoff Frampton, Southampton Health Technology Assessment Centre, Present for notes 9 to 12
* Neelam Kalita, Southampton Health Technology Assessment Centre, Present for notes 9 to 12
* Louise Crathorne, Peninsular Technology Assessment Group, Present for notes 16 to 20
* Simone Critchlow, Peninsular Technology Assessment Group, Present for notes 16 to 20

## Clinical & Patients experts in attendance:

* Peter Clark, CDF Clinical Lead, NHS England, Present for all notes
* Robert Burley, Patient Expert, Nominated by Muscular Dystrophy UK, Present for notes 1 to 5
* Fiona Marley, Head of Highly Specialised Commissioning, NHS England, Present for notes 1 to 5
* Dr Emma Matthews, Consultant Neurologist, National Hospital of Neurology, Present for notes 1 to 5
* Dr Fiona Norwood, Consultant Neurologist & Honorary Senior Lecturer, King’s College Hospital, London, Present for notes 1 to 5
* David Lockyer, Patient Expert, Nominated by Muscular Dystrophy UK, Present for notes 1 to 5
* Dr Charlotte Benson, Consultant medical oncologist, The Royal Marsden NHS Foundation Trust, Present for notes 9 to 12
* Dr Ramesh Bulusu, Consultant Oncologist and Network GIST Lead, Cambridge University Hospitals, Present for notes 9 to 12
* Bradley Price – Patient Expert, Nominated by Sarcoma UK, Present for notes 9 to 12
* Jane Lochrie, Patient Expert, Nominated by GIST Cancer UK, Present for notes 9 to 12
* Professor Samreen Ahmed, Consultant Medical Oncologist, NCRI/RCP/BTOG/ACP, Present for notes 16 to 20
* Paula Shepherd, Patient expert, Nominated by Lung Cancer Nursing UK, Present for notes 16 to 20
* Dr Yvonne Summers, Consultant Medical Oncologist, The Christie NHS foundation Trust, Present for notes 16 to 20

## Other Non-public attendees:

* Hayley Garnet, Senior Medical Editor, NICE, Present for notes 1 to 8
* Stevie Okoro, Technical analyst - Commercial risk, NICE, Present for notes 1 to 8
* Sarah Jackson. NIHRIO, Present for notes 1 to 5 & 9 to 12
* Kim Tuyen Dangova, NIHRIO, Present for notes 1 to 5 & 9 to 12
* Adriana Robayo, IETS International, Present for notes 9 to 12
* Andrea Lara, IETS International, Present for notes 9 to 12
* Jazmin Pinzon IETS International, Present for notes 9 to 12
* Lorena Mesa-Melgarejo, IETS International, Present for notes 9 to 12
* Luz Barragan, IETS International, Present for notes 9 to 12
* Kelly Estradorozco, IETS International, Present for notes 9 to 12
* Steven Robinson, Scientific Adviser, NICE, Present for notes 9 to 15
* Harry Atkins, Assistant Project Manager, NICE, Present for notes 9 to 15
* Diana O’Rourke, Senior Analyst, NICE, Present for notes 9 to 15
* Claire Hawksworth, Technical Analyst – Evidence Generation, NICE, present for notes 9 to 15
* Emilene Coventry, Senior Medical Editor, NICE, Present for notes 9 to 15
* Ann Greenwood, Senior Medical Editor, NICE, Present for notes 16 to 23
* Maroulla Whiteley, Business Analyst, NICE, Present for all notes
* Verena Wolfram, HTA Analyst, NICE, Present for notes 16 to 23
* Ross Wilkinson, HTA Analyst, NICE, Present for notes 16 to 23

### Notes

## Appraisal of Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders [ID1488]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group [ERG] representatives and representatives from Lupin Pharmaceuticals.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.

	1. Matt Bradley declared a non-financial professional & personal Interest as he is an employee of the comparator manufacturer, GSK.
		1. It was agreed that this declaration would not prevent Matt from participating in discussions on this topic.
	2. Dr Fiona Norwood declared a financial Interest as she has received honorarium from Lupin for attending advisory boards
		1. It was agreed that this declaration would not prevent Fiona from participating in discussions on this topic.
	3. Dr Emma Matthews declared a financial Interest as she has received honorarium from Lupin for attending advisory boards in 2018.
		1. It was agreed that this declaration would not prevent Emma from participating in discussions on this topic.
	4. Robert Burley declared a financial Interest as nominating organisation Musclular Dystrophy UK has received financial aid for conferences and donations for running the helpline.
		1. It was agreed that this declaration would not prevent Robert from participating in discussions on this topic.
	5. No further conflicts of interest were declared for this appraisal.
3. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
4. The Chair asked the company representatives whether they wished to comment on any matters of factual inaccuracy.

### Part 2 – Closed session [company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting]

1. Agreement on the content of the Appraisal Consultation Document [ACD] was discussed by the committee.
2. The committee decision was based on consensus
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] in line with their decisions.

## Appraisal of Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group [ERG] representatives and representatives from Blueprint Medicines.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests
	1. No conflicts of interest were declared for this appraisal.
3. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] received from consultees, commentators and through the NICE website
4. The Chair asked the company representatives whether they wished to comment on any matters of factual inaccuracy.

### Part 2 – Closed session [company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting]

1. Agreement on the content of the Appraisal Consultation Document [ACD] was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] in line with their decisions.

## Appraisal of Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer - CDF Review of TA557 [ID1584]

### Part 1 – Open session

1. The Chair welcomed the invited Evidence Review Group [ERG] representatives and representatives from MSD.
2. The Chair asked all committee members, ERG representatives and NICE staff present to declare any relevant interests.
	1. Professor David Meads declared a non-financial professional & personal interest as the University of Leeds has received funding from Celgene and Sanofi for research in unrelated areas.
		1. It was agreed that this declaration would not prevent David from participating in this section of the meeting.
	2. Dr Yvonne Summers declared a personal interest as she has carried put advisory board work for MSD but not preceding the last 12 months.
		1. It was agreed that this declaration would not prevent Yvonne from participating in this section of the meeting.
	3. Professor Samreen Ahmed declared a personal interest as he has received consultancy and speaker fees from MERCK and travel grants for international meetings.
		1. It was agreed that this declaration would not prevent Samreen from participating in this section of the meeting.
3. No further conflicts of interest were declared for this appraisal.
4. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy before opening for discussions.

### Part 2 – Closed session [company representatives, ERG representatives and members of the public were asked to leave the meeting]

1. Agreement on the content of the Appraisal Consultation Document [ACD] was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] in line with their decisions.